Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine

Vaccine
P E TarrT Jones

Abstract

Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) has been shown to augment antigen presentation by macrophages and dendritic cells in vitro, and to increase antibody responses to injected antigens in experimental animals. To evaluate the usefulness of rhGM-CSF as a vaccine adjuvant, 108 healthy volunteers were randomly assigned to receive an injection of rhGM-CSF (n = 81) or placebo (control group; n = 27), followed by an injection with recombinant hepatitis B vaccine into the same site. During the study period of 28 days, protective antibody titers to hepatitis surface antigen (anti-HBs10 mIU ml-1) were observed in 11 of 81 subjects receiving rhGM-CSF, but in none of the controls (P = 0.035). Injections were well tolerated. A single i.m. or s.c. injection of 20-40 micrograms of rhGM-CSF significantly enhances antibody responses when given at the same site as recombinant hepatitis B vaccination.

References

Aug 31, 1991·Lancet·K HoekmanH M Pinedo
Feb 6, 1992·The New England Journal of Medicine·F E Nathan, E C Besa
Apr 1, 1990·The Journal of Experimental Medicine·J W Young, R M Steinman
Jan 1, 1994·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E LiehlP Mayer
Jan 1, 1993·Vaccine·R K GuptaC K Gupta
May 14, 1993·Science·A Lanzavecchia

❮ Previous
Next ❯

Citations

Jan 25, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H MellstedtA Osterborg
Apr 27, 2007·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Lois A Nelson
Jul 31, 1998·Immunology and Cell Biology·J Kovarik, C A Siegrist
May 21, 2005·Journal of Immune Based Therapies and Vaccines·Pierre Antoine Brown, Jonathan B Angel
Dec 7, 2014·Clinical Reviews in Allergy & Immunology·Xuefen LiYu Chen
Nov 27, 2007·Vaccine·David A ZaharoffJohn W Greiner
Feb 27, 2003·Pediatric Transplantation·Deborah C Molrine
Jul 10, 2008·Expert Opinion on Drug Metabolism & Toxicology·Xavier Thomas
Aug 23, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Andreas BråveBritta Wahren
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramesh K RamanathanDonald L Trump
Apr 17, 2001·Infectious Disease Clinics of North America·D C Molrine, P L Hibberd
Oct 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·D HaddadW R Weiss
Jun 10, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christos E KyriakopoulosDouglas G McNeel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.